R Squared Ltd Purchases Shares of 6,770 CRISPR Therapeutics AG $CRSP

R Squared Ltd purchased a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 6,770 shares of the company’s stock, valued at approximately $329,000.

Several other large investors have also recently bought and sold shares of the company. ARK Investment Management LLC boosted its holdings in CRISPR Therapeutics by 13.3% in the 1st quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company’s stock valued at $345,929,000 after purchasing an additional 1,192,336 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in CRISPR Therapeutics by 182.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,952,751 shares of the company’s stock valued at $66,452,000 after purchasing an additional 1,262,560 shares during the period. Vanguard Group Inc. boosted its holdings in CRISPR Therapeutics by 1.9% in the 1st quarter. Vanguard Group Inc. now owns 1,769,709 shares of the company’s stock valued at $60,223,000 after purchasing an additional 33,711 shares during the period. Orbis Allan Gray Ltd boosted its holdings in CRISPR Therapeutics by 5.9% in the 1st quarter. Orbis Allan Gray Ltd now owns 1,562,932 shares of the company’s stock valued at $53,187,000 after purchasing an additional 86,813 shares during the period. Finally, Millennium Management LLC boosted its holdings in CRISPR Therapeutics by 6,769.1% in the 1st quarter. Millennium Management LLC now owns 583,733 shares of the company’s stock valued at $19,864,000 after purchasing an additional 575,235 shares during the period. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $67.61 on Friday. CRISPR Therapeutics AG has a 52-week low of $30.04 and a 52-week high of $78.48. The company has a market capitalization of $6.15 billion, a P/E ratio of -12.45 and a beta of 1.84. The company has a fifty day moving average of $61.62 and a 200-day moving average of $51.27.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, August 4th. The company reported ($1.29) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.18. The business had revenue of $0.89 million during the quarter, compared to the consensus estimate of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The firm’s revenue for the quarter was up 72.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.49) earnings per share. As a group, analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on CRSP shares. Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Friday. Royal Bank Of Canada raised their price target on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the company a “sector perform” rating in a report on Tuesday, August 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $81.00 price objective on shares of CRISPR Therapeutics in a report on Friday, October 10th. Bank of America lifted their price objective on shares of CRISPR Therapeutics from $78.00 to $93.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Finally, Barclays lifted their price objective on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Ten investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $72.59.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 50,895 shares of the business’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $67.91, for a total value of $3,456,279.45. Following the completion of the sale, the chief executive officer directly owned 254,201 shares of the company’s stock, valued at $17,262,789.91. The trade was a 16.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, General Counsel James R. Kasinger sold 1,076 shares of the business’s stock in a transaction on Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total transaction of $71,661.60. Following the completion of the sale, the general counsel directly owned 83,402 shares of the company’s stock, valued at $5,554,573.20. This represents a 1.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 56,213 shares of company stock valued at $3,810,458 over the last three months. 4.30% of the stock is currently owned by insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.